RenovoRx, Inc.RNXTEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapy delivery systems for cancer treatment. Its core assets include proprietary transarterial delivery platforms, with primary operations in the United States, serving unmet medical needs in the oncology care segment.
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-03 | VOLL MARK | Chief Financial Officer | Grant | 80.0K | $0.00 | $0 |
| 2026-03-25 | VOLL MARK | Chief Financial Officer | Grant | 12.4K | $0.00 | $0 |
| 2026-03-20 | Laurence Marton | Director | Buy (open market) | 9.7K | — | — |
| 2026-03-20 | VOLL MARK | Chief Financial Officer | Buy (open market) | 97.2K | — | — |
| 2026-03-20 | Shaun Bagai | Chief Executive Officer | Buy (open market) | 24.3K | — | — |
1–5 of 5